Mary Ann Liebert: Using Urine NAA Levels to Distinguish Between Mild and Typical Canavan Disease
December 07, 2024
December 07, 2024
NEW ROCHELLE, New York, Dec. 7 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new study shows that urine levels of N-acetylaspartate (NAA), which accumulates in the urine of patients with the autosomal recessive leukodystrophy Canavan disease, can be used to distinguish between mild and typical forms of the disease. The study is published in the peer-reviewed journal Human Gene Therapy. Click here (https://www.liebertpub.com/doi/10.1089/hum.2024.168) to read . . .
A new study shows that urine levels of N-acetylaspartate (NAA), which accumulates in the urine of patients with the autosomal recessive leukodystrophy Canavan disease, can be used to distinguish between mild and typical forms of the disease. The study is published in the peer-reviewed journal Human Gene Therapy. Click here (https://www.liebertpub.com/doi/10.1089/hum.2024.168) to read . . .